Cigna Appoints Phil Austin to Lead Individual Cigna Global Health Options (CGHO) Business

GLASGOW, Scotland, November 15, 2011 /PRNewswire/ --

  • Phil Austin appointed as Global Head Individual Private Medical Insurance (PMI) for CGHO.
  • Takes the lead in developing growth strategy in key global markets and supporting all distribution channels.  

Cigna (NYSE:CI), a global leader in serving expatriates and other globally mobile individuals, has appointed Phil Austin to lead Cigna's international individual PMI business - Cigna Global Health Options (http://www.cignaglobal.com).

Reporting to Michael J. Ross, Senior Vice President of Individual Private Medical Insurance (IPMI) and Business Development for Cigna International, Mr. Austin will be responsible for developing and implementing the company's individual consumer strategy on an international scale and creating a world-class international individual business.

"We're very pleased to have Phil take on this important role for Cigna Global Health Options," said Ross. "With Phil's wealth of experience in the healthcare industry, his proven leadership and track record in achieving results, I've no doubt that he'll be successful in this new role and will help Cigna International better serve individual expatriates and local citizens around the globe."

Mr. Austin will be responsible for building the business segment and driving profitable growth, targeting high net worth and globally mobile individuals through various channels such as the internet, bancassurance and intermediaries in key global markets.

"I'm excited to assume this role. This is an excellent opportunity to strengthen Cigna's position as the premier provider of products and solutions that support the health, well-being and sense of security of consumers in the global individual market," said Austin.

Mr. Austin brings over 20 years of experience in global sales, marketing, product strategy and general management to the CGHO team.  He returns to Cigna after serving as Vice President of the European Group A&H (Accident and Health) Business for Chartis.  Mr. Austin first joined Cigna International in 2002 as Partnership Director for the UK business.  He went on to hold several positions within the organisation, including Health, Life & Accident (HL&A) Europe Sales & Marketing Director and Interim CEO for HL&A Europe.

Notes to editors:

The Cigna Global Health Options plan is designed for customers who want the flexibility of having easy access to high quality health care around the world.

The 'core' International Medical Insurance covers hospitalisation, surgery, emergency care, cancer treatment, and maternity care. All customers then have the flexibility to customise their overall solution by choosing from a range of four additional options:


For more information, please visit http://www.cignaglobal.com

About Cigna

Cigna (NYSE: CI) is a global health service and financial company dedicated to helping people improve their health, well-being and sense of security. Cigna Corporation's operating subsidiaries in the United States provide an integrated suite of health services, such as medical, dental, behavioral health, pharmacy and vision care benefits, as well as group life, accident and disability insurance.

Cigna maintains sales capability in 30 countries and jurisdictions and has approximately 66 million customer relationships throughout the world. All products and services are provided exclusively by such operating subsidiaries and not by Cigna Corporation. To learn more about Cigna, visit http://www.cigna.com. To sign up for email alerts or RSS feed of company news, log on to http://newsroom.cigna.com/section_display.cfm?section_id=18  

SOURCE Cigna

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.